Desk›Healthcare› GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd
BSE 500660 · NSE GLAXO · ISIN INE159A01016 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹3,068.35
+1.35%
BSE close, 28 August 2026
₹51,979.70 cr
16.9 cr shares · Mid cap
₹12,657.26 cr
as published
49.0× · 31.04×
EPS ₹62.60 · BV ₹98.85
3,790.20 / 1,011.82
₹ cr, as filed
24
6 selected · 25%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -1.5% |
|---|---|
| Against 52-week low | +47.0% |
| Day change | +1.35% |
| Size band | Mid cap |
| Index membership | NIFTY 500 |
Valuation as published by BSE
| Earnings per share | ₹62.60 |
|---|---|
| Price / earnings | 49.02× |
| Price / book | 31.04× |
| Book value — derived, price ÷ P/B | ₹98.85 |
| Return on equity | 63.32% |
| Operating margin | 38.38% |
| Net margin | 27.40% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 63.32%
- ROE as published
- 63.32%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 924.42 | 253.33 | 14.95 | 38.38% | 27.40% |
| Mar-26 · Q | 989.15 | 274.94 | 16.23 | 38.71% | 27.80% |
| FY25-26 | 3,790.20 | 1,011.82 | 59.00 | 38.14% | 26.70% |
Quarter on quarter
- Revenue, quarter on quarter
- -6.5%
- Net profit, quarter on quarter
- -7.9%
- Operating margin, quarter on quarter
- -33 bps
Disclosure profile 24 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Change in Directorate | 1 |
| Change in Management | 1 |
| Press Release | 1 |
| Resignation | 1 |
| Results | 1 |
| Selected sub-total | 6 |
| Procedural | |
| Analyst / Investor Meet | 5 |
| Postal Ballot | 4 |
| General | 3 |
| Newspaper Publication | 3 |
| Board Meeting | 1 |
| Clarification | 1 |
| Trading Window | 1 |
| Procedural sub-total | 18 |
| Total | 24 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
24 filings · 6 selected · busiest 2026-08-03
Filing rhythm · the twelve most recent
2026-08-062026-09-25
SelectedProcedural
Filings
24 in the window · 10 earlier on record
-
25 September 2026 ·
Closure of Trading Window
As per attachment
Insider Trading / SAST / Closure of Trading Window View filing →
-
15 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
As per attachment
AGM/EGM / Postal Ballot View filing →
-
15 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Outcome of Postal Ballot
AGM/EGM / Postal Ballot View filing →
-
2 September 2026 ·
-
1 September 2026 ·
Corrigendum To The Notice Of Postal Ballot Dated August 3, 2026
As per attachment
AGM/EGM / Postal Ballot View filing →
-
26 August 2026 ·
-
26 August 2026 ·
Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd
The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Ltd on August 26, 2026, with reference to Movement in Volume. The reply is awaited.
Company Update / Clarification
-
19 August 2026 ·
-
14 August 2026 ·
-
13 August 2026 ·
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
As per attachment
AGM/EGM / Postal Ballot View filing →
-
6 August 2026 ·
-
6 August 2026 ·
-
5 August 2026 ·
Analyst / Investor Meet - Outcome
As per attachment
Company Update / Analyst / Investor Meet View filing →
-
4 August 2026 ·
-
3 August 2026 ·
Analyst / Investor Meet - Outcome
As per attachment
Company Update / Analyst / Investor Meet View filing →
-
3 August 2026 ·
Change in Management
Reappointment of Managing Director
Company Update / Change in Management View filing →
-
3 August 2026 ·
-
3 August 2026 ·
-
3 August 2026 ·
Press Release / Media Release
As per attachment
Company Update / Press Release / Media Release View filing →
-
3 August 2026 ·
Analyst / Investor Meet - Outcome
Presentation
Company Update / Analyst / Investor Meet View filing →
-
3 August 2026 ·
-
3 August 2026 ·
Board Meeting Outcome for Outcome Of Meeting
Outcome of Meeting
Board Meeting / Outcome of Board Meeting View filing →
-
21 July 2026 ·
Analyst / Investor Meet - Intimation
As per attachment
Company Update / Analyst / Investor Meet View filing →
-
21 July 2026 ·
Board Meeting Intimation for Approve And Take On Record The Un-Audited Financial Results For The First Quarter Ended 30Th June 2026.
Glaxosmithkline Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 ,inter alia, to consider and approve approve and ....
Board Meeting / Board Meeting View filing →
RSS feed for GlaxoSmithKline Pharmaceuticals Ltd · the 50 most recent filings